AZ, Daiichi Sankyo file Dato-DXd for second indication

AZ, Daiichi Sankyo file Dato-DXd for second indication

Submitted by admin on April 2, 2024 - 11:31am
Source: 
Pharmaphorum
News Tags: 
AstraZeneca
Daiichi Sankyo
Dato-DXd
breast cancer
Headline: 
AZ, Daiichi Sankyo file Dato-DXd for second indication
snippet: 

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for breast cancer.

Do Not Allow Advertisers to Use My Personal information